Christopher Kaiser

1.1k total citations
35 papers, 856 citations indexed

About

Christopher Kaiser is a scholar working on Oncology, Psychiatry and Mental health and Surgery. According to data from OpenAlex, Christopher Kaiser has authored 35 papers receiving a total of 856 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 9 papers in Psychiatry and Mental health and 5 papers in Surgery. Recurrent topics in Christopher Kaiser's work include Schizophrenia research and treatment (8 papers), Colorectal Cancer Treatments and Studies (4 papers) and Cancer Treatment and Pharmacology (4 papers). Christopher Kaiser is often cited by papers focused on Schizophrenia research and treatment (8 papers), Colorectal Cancer Treatments and Studies (4 papers) and Cancer Treatment and Pharmacology (4 papers). Christopher Kaiser collaborates with scholars based in United States, United Kingdom and Belgium. Christopher Kaiser's co-authors include Bruce J. Kinon, Sara Kollack‐Walker, Saeed Ahmed, Craig Mallinckrodt, William O. Herring, Geert Molenberghs, John G. Watkin, Raymond J. Carroll, John Kennedy and Haoda Fu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Christopher Kaiser

34 papers receiving 815 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher Kaiser United States	18	270	157	100	89	89	35	856
Phillip W. Lavori United States	16	236 0.9×	55 0.4×	70 0.7×	150 1.7×	31 0.3×	22	1.3k
Baoguang Han United States	16	131 0.5×	87 0.6×	121 1.2×	707 7.9×	84 0.9×	26	1.1k
Pritibha Singh United States	13	88 0.3×	169 1.1×	47 0.5×	33 0.4×	96 1.1×	30	567
Yeh‐Fong Chen United States	10	134 0.5×	354 2.3×	31 0.3×	198 2.2×	21 0.2×	17	1.0k
Galen E.B. Wright Canada	22	79 0.3×	221 1.4×	54 0.5×	490 5.5×	320 3.6×	53	1.2k
Paweł Kalinowski Poland	14	107 0.4×	48 0.3×	226 2.3×	256 2.9×	38 0.4×	66	898
Barbara van Zwieten‐Boot Netherlands	9	187 0.7×	102 0.6×	39 0.4×	95 1.1×	12 0.1×	11	502
Ruth Farmer United Kingdom	20	38 0.1×	133 0.8×	221 2.2×	355 4.0×	67 0.8×	35	1.2k
César A. Rodríguez Spain	20	100 0.4×	627 4.0×	138 1.4×	221 2.5×	92 1.0×	73	1.4k
Philip Rotella United States	12	152 0.6×	80 0.5×	303 3.0×	105 1.2×	18 0.2×	13	997

Countries citing papers authored by Christopher Kaiser

Since Specialization

Citations

This map shows the geographic impact of Christopher Kaiser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Kaiser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Kaiser more than expected).

Fields of papers citing papers by Christopher Kaiser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Kaiser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Kaiser. The network helps show where Christopher Kaiser may publish in the future.

Co-authorship network of co-authors of Christopher Kaiser

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Kaiser. A scholar is included among the top collaborators of Christopher Kaiser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Kaiser. Christopher Kaiser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ehrlich, Adam C., et al.. (2025). Long-Term Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis: An Integrated 2-Year Safety Analysis. The American Journal of Gastroenterology. 120(12). 2857–2866.

Raje, Noopur, Edward A. Faber, Paul G. Richardson, et al.. (2016). Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research. 22(23). 5688–5695. 22 indexed citations

Koskinas, Konstantinos C., Masanori Taniwaki, Fabio Rigamonti, et al.. (2016). Impact of Patient and Lesion Complexity on Long-Term Outcomes Following Coronary Revascularization With New-Generation Drug-Eluting Stents. The American Journal of Cardiology. 119(4). 501–507. 9 indexed citations

Raje, Noopur, Philippe Moreau, Evangelos Terpos, et al.. (2016). Phase 2 study of tabalumab, a human anti‐B‐cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. British Journal of Haematology. 176(5). 783–795. 38 indexed citations

Chao, Albert H., et al.. (2014). The Differential Impact of Plastic Surgery Subspecialties on the Financial Performance of an Academic Clinical Practice. Plastic & Reconstructive Surgery. 133(6). 748e–755e. 5 indexed citations

Luca, Giuseppe De, Maurits T. Dirksen, Christian Spaulding, et al.. (2013). Meta-Analysis Comparing Efficacy and Safety of First Generation Drug-Eluting Stents to Bare-Metal Stents in Patients With Diabetes Mellitus Undergoing Primary Percutaneous Coronary Intervention. The American Journal of Cardiology. 111(9). 1295–1304. 25 indexed citations

Ryan, Christopher W., Mark Agulnik, Antonio López–Pousa, et al.. (2012). A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma. Investigational New Drugs. 31(1). 145–151. 13 indexed citations

Raje, Noopur, Edward A. Faber, Paul G. Richardson, et al.. (2012). Phase 1 Study of Tabalumab, a Human Anti-BAFF Antibody and Bortezomib in Patients with Previously-Treated Multiple Myeloma. Blood. 120(21). 447–447. 10 indexed citations

Vergote, Ignace, Hilary Calvert, Marek Kania, et al.. (2009). A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. European Journal of Cancer. 45(8). 1415–1423. 40 indexed citations

10.

Gustavsson, Bengt, Christopher Kaiser, Göran Carlsson, et al.. (2008). Molecular determinants of efficacy for 5‐FU‐based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy‐related genes. International Journal of Cancer. 124(5). 1220–1226. 33 indexed citations

11.

Scagliotti, Giorgio V., Christopher Kaiser, Bonne Biesma, et al.. (2007). C6-01: Correlations of biomarker expression and clinical outcome in a large phase III trial of pemetrexed plus cisplatin or gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2(8). S375–S375. 9 indexed citations

12.

Underhill, Craig, David Goldstein, Vera Gorbounova, et al.. (2007). A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer. Oncology. 73(1-2). 9–20. 16 indexed citations

13.

Battaglia, John, John P. Houston, Jonna Ahl, Adam L. Meyers, & Christopher Kaiser. (2005). A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia. Clinical Therapeutics. 27(10). 1612–1618. 5 indexed citations

14.

Kennedy, John, Walter Deberdt, Alan P. Siegal, et al.. (2005). Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia. International Journal of Geriatric Psychiatry. 20(11). 1020–1027. 33 indexed citations

15.

Mallinckrodt, Craig, Michael J. Detke, Christopher Kaiser, et al.. (2005). Comparing onset of antidepressant action using a repeated measures approach and a traditional assessment schedule. Statistics in Medicine. 25(14). 2384–2397. 5 indexed citations

16.

Kennedy, John, Dilip V. Jeste, Christopher Kaiser, et al.. (2003). Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double‐blind controlled trial. International Journal of Geriatric Psychiatry. 18(11). 1013–1020. 30 indexed citations

17.

Feldman, Peter D., Christopher Kaiser, John Kennedy, et al.. (2003). Comparison of Risperidone and Olanzapine in the Control of Negative Symptoms of Chronic Schizophrenia and Related Psychotic Disorders in Patients Aged 50 to 65 Years. The Journal of Clinical Psychiatry. 64(9). 998–1004. 26 indexed citations

18.

Kennedy, John, Frank P. Bymaster, Leslie M. Schuh, et al.. (2001). A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data. International Journal of Geriatric Psychiatry. 16(S1). S33–S61. 29 indexed citations

19.

Reverter, Antônio, Christopher Kaiser, & Craig Mallinckrodt. (1998). A bootstrap approach to confidence regions for genetic parameters from Method R estimates.. Journal of Animal Science. 76(9). 2263–2263. 7 indexed citations

20.

Reverter, Antônio & Christopher Kaiser. (1997). The role of different pedigree structures on the sampling variance of heritability estimates.. Journal of Animal Science. 75(9). 2355–2355. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact